Brainstorm Cell Therapeutics Inc. (BCLI)
EBITDA Growth
16.37%
TTM · Period ending:
BCLI EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported16.37%period ending
Latest reported16.37%period ending
BCLI TTM EBITDA YoY % (-189.92% → 16.37%)
Year-over-year change
High-resolution chart · PNG
BCLI ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 16.3728% | |
| 27.7649% | |
| 14.8345% | |
| 22.6698% | |
| 30.4938% | |
| 37.3249% | |
| 47.8176% | |
| 35.0172% | |
| 23.8746% | |
| 20.4211% | |
| 10.5514% | |
| 17.6241% | |
| 9.0265% | |
| -6.1722% | |
| -1.0626% | |
| 12.6167% | |
| 15.669% | |
| 24.1471% | |
| 22.8381% | |
| -6.9106% | |
| -0.1566% | |
| -14.7337% | |
| -37.7808% | |
| -33.9907% | |
| -56.8411% | |
| -58.3328% | |
| -63.6709% | |
| -149.5224% | |
| -146.2438% | |
| -204.208% | |
| -183.9438% | |
| -42.407% | |
| -47.0553% | |
| -9.6293% | |
| 1.8378% | |
| -0.8158% | |
| 24.3082% | |
| 38.4348% | |
| 40.7504% | |
| 40.6572% | |
| 30.0952% | |
| 5.063% | |
| -15.4708% | |
| -60.4363% | |
| -103.4681% | |
| -73.3619% | |
| -48.0874% | |
| -48.2725% | |
| -12.8451% | |
| -38.7819% | |
| -48.6909% | |
| -0.9899% | |
| -15.4379% | |
| 14.9807% | |
| 12.5756% | |
| -30.0612% | |
| -20.2667% | |
| -85.4399% | |
| -61.1959% | |
| -62.585% | |
| -56.9859% | |
| -23.0896% | |
| -34.7429% | |
| -25.7237% | |
| -17.6724% | |
| -9.1837% | |
| 12.1486% | |
| 44.1587% | |
| 42.837% | |
| 37.0585% | |
| 19.8461% | |
| 24.6315% | |
| 11.7195% | |
| 19.058% | |
| 10.6527% | |
| -220.3041% | |
| -139.312% | |
| -128.3047% | |
| -90.184% | |
| 93.7355% | |
| 92.8976% | |
| 92.2286% | |
| 91.9694% | |
| -1,011.6446% | |
| -38,074.4728% | |
| -38,921.449% | |
| -79,971.264% | |
| -8,491.7962% | |
| -188.4946% | |
| -189.9153% |